The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial

Clinical Rehabilitation

Volumn 32, Issue 8, 2018, Pages 1069-1075

  Asadollahi, Marjan ^a   Ramezani, Mahtab ^a   Khanmoradi, Ziba ^a   Karimialavijeh, Ehsan ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

citalopram; fluoxetine; Ischemic stroke; motor function; placebo controlled

Indexed keywords

CITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PHYSIOTHERAPY; RANDOMIZED CONTROLLED TRIAL;

CITALOPRAM; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PHYSICAL THERAPY MODALITIES; SEROTONIN UPTAKE INHIBITORS; STROKE;

EID: 85047421451     PISSN: 02692155     EISSN: 14770873     Source Type: Journal    
DOI: 10.1177/0269215518777791     Document Type: Article

References (14)

1. Go AS, Mozaffarian D, Roger VL. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 2013; 127: e6–e245
2. Siepmann T, Penzlin AI, Kepplinger J. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav 2015; 5: e00373
3. Langhorne P, Coupar F, Pollock A. Motor recovery after stroke: a systematic review. Lancet Neurol 2009; 8: 741–754
4. Chollet F, Cramer SC, Stinear C. Pharmacological therapies in post stroke recovery: recommendations for future clinical trials. J Neurol 2014; 261: 1461–1468
5. Pariente J, Loubinoux I, Carel C. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001; 50: 718–729
6. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007; 18: 391–418
7. Gu S-C, Wang C-D. Early selective serotonin reuptake inhibitors for recovery after stroke: a meta-analysis and trial sequential analysis. J Stroke Cerebrovasc Dis 2018; 27: 1178–1189
8. Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol 2008; 63: 549–560
9. Pekna M, Pekny M, Nilsson M. Modulation of neural plasticity as a basis for stroke rehabilitation. Stroke 2012; 43: 2819–2828
10. Sullivan KJ, Tilson JK, Cen SY. Fugl-Meyer assessment of sensorimotor function after stroke. Stroke 2011; 42: 427–432
11. Lyden P, Brott T, Tilley B. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994; 25: 2220–2226
12. Chollet F, Tardy J, Albucher J-F. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 123–130
13. Acler M, Robol E, Fiaschi A. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol 2009; 256: 1152–1158
14. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 2008; 22: 311–314